Apollomics, Inc.
APLMHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeApollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to. The company carries a $79.6M market cap, placing it firmly in the micro-cap category. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Market Cap
$79.6M
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-42.30
EPS (TTM)
$-7.43
EPS (Fwd)
$-0.65
ROE
-1305.4%
ROA
-57.6%
Cash
$3.3M
Total Debt
$643,000
Free CF
-$9.8M
52W Change
416.1%
Annual Financials
Cash vs Debt
Where APLM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, APLM finished 52.79% above its 150-day moving average ($17.90) and 52.28% above its 200-day moving average ($17.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APLM overbought or oversold?
At the September 3, 2026 close, APLM's RSI(14) was 85.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Apollomics, Inc. holds $3.3M in cash against $643K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$9.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -1305.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, APLM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing APLM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.